- 作者：Yaacov Richard Lawrence ; Adam P Dicker
- 关键词：Concrete structures ; Cracking ; Creep ; Finite elements ; Serviceability ; Shrinkage
- 刊名：Lancet Oncology
- 出版年：2008
- 出版时间：April 2008
- 年：2008
- 卷：9
- 期：4
- 页码：308-309
- 全文大小：45 K
Findings
Between Oct 12, 1995, and Feb 5, 2002, 308 patients were identified from two prospective, randomised trials at the Royal Marsden Hospital, London and Sutton, UK, for the radiotherapy cohort and diagnostic biopsies were available for 201 of these patients. Between June 6, 1995, and Nov 4, 2005, 329 patients were identified from the Aarhus University Hospital, Skejby, Denmark, for the prostatectomy cohort; of these, 40 patients were excluded because the tumour was too small to sample (19 patients), because the paraffin block was too thin (19 patients), or because the blocks were missing (two patients), leaving 289 patients for analysis. For patients treated with radiotherapy, increased staining for VEGF (p=0·008) and HIF-1 alpha (p=0·02) expression, but not increased osteopontin expression (p=0·978), were significant predictors of a shorter time to biochemical failure on multivariate analysis, independent of clinical tumour stage, Gleason score, serum PSA concentration, and dose of radiotherapy. For patients treated with surgery, increased staining for VEGF (p<0·0001) and HIF-1 alpha (p<0·0001) expression, and increased osteopontin expression (p=0·0005) were each significantly associated with a shorter time to biochemical failure on multivariate analysis, independent of pathological tumour stage, Gleason score, serum PSA concentration, and margin status.
Interpretation
To our knowledge, this is the largest study of intrinsic markers of hypoxia and angiogenesis in relation to the outcome of radical treatment of localised prostate cancer. Increased expression of VEGF, HIF-1 alpha, and, for patients treated with surgery, osteopontin, identifies patients at high risk of biochemical failure who would be suitable for enrolment into trials of treatment intensification.
Funding
Prostate Cancer Research Foundation, London, UK; Danish Cancer Society, Copenhagen, Denmark; Cancer Research UK, London, UK; and National Cancer Research Institute South of England Prostate Cancer Collaborative, London, UK.